Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) (TEPTAU)

Trial Profile

Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) (TEPTAU)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Acronyms TEPTAU

Most Recent Events

  • 08 Sep 2022 Status changed from active, no longer recruiting to completed.
  • 06 Nov 2019 According to European Clinical Trials Database record, trial is completed.
  • 25 Sep 2019 Planned End Date changed from 1 Sep 2018 to 25 Nov 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top